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Abstract
A prophylactic vaccine is needed to slow the spread of HIV-1 infection. Optimization of the wild-type envelope
glycoproteins to create immunogens that can elicit effective neutralizing antibodies is a high priority. Starting with ten
genes encoding subtype B HIV-1 gp120 envelope glycoproteins and using in vitro homologous DNA recombination, we
created chimeric gp120 variants that were screened for their ability to bind neutralizing monoclonal antibodies. Hundreds
of variants were identified with novel antigenic phenotypes that exhibit considerable sequence diversity. Immunization of
rabbits with these gp120 variants demonstrated that the majority can induce neutralizing antibodies to HIV-1. One novel
variant, called ST-008, induced significantly improved neutralizing antibody responses when assayed against a large panel
of primary HIV-1 isolates. Further study of various deletion constructs of ST-008 showed that the enhanced immunogenicity
results from a combination of effective DNA priming, an enhanced V3-based response, and an improved response to the
constant backbone sequences.
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Introduction
A critical objective in the search for a vaccine to HIV-1 is the
identification of immunogens that can elicit antibodies capable of
neutralizing a broad array of clinically relevant viruses [1–3]. The
viral envelope glycoprotein (Env) is central to vaccine research
since it is the only target for neutralizing antibodies [1,4,5]. The
Env consists of the gp120 surface glycoprotein and the gp41
transmembrane protein associated in a trimer of gp120-gp41
heterodimers. The existence of broadly neutralizing sera from
some HIV-1 infected individuals [1,6–10] and the protection in
monkeys by passive transfer of several neutralizing monoclonal
antibodies (mAbs) [11–16] suggest that if a suitable antibody
response to Env can be obtained, then protection from infection
will be possible. However, a large clinical trial using a recombinant
version of monomeric gp120 failed to provide any evidence of
protection [17]. More recently, the combination of a viral vaccine
and recombinant protein resulted in limited but significant
protection from infection [18]. It is not known which immune
responses are responsible for this result.
HIV-1 virus has evolved multiple mechanisms to evade immune
surveillance that include extensive glycosylation, hypervariability
of amino acid sequences, conformational masking and inaccessi-
bility of conserved sites [1–3,19]. The major challenge to creating
an Env-based antibody-inducing vaccine is the identification of
conserved neutralizing epitopes that are both immunogenic
enough to induce antibodies and accessible on the virus.
Several forms of Env have been evaluated for immunogenicity
including gp120 monomers, soluble gp140 oligomers, and Env-
containing virus-like particles [17,20–34]. Attempts have been
made to delete certain variable regions [35,36], create hypergly-
cosylated forms [37,38], constrain the CD4-binding conformation
of the protein [26,32], and immunize with mixtures of wild-type
sequences [33,34], in the hope of directing the humoral immune
response to more conserved epitopes while limiting the immuno-
genicity of dominant but non-neutralizing epitopes. For gp140-
based immunogens, efforts have focused on stabilizing and
increasing trimerization to mimic the conformation of the
functional Env spikes on HIV-1 virions [21–25,30,31,39].
Additionally, computational approaches have been used to deduce
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and group M Env proteins in an effort to overcome sequence
diversity [40–43]. Some increased potency of the neutralizing
antibodies induced by certain Env formats has been claimed;
however, the breadth of neutralization is still so limited that an
HIV vaccine able to induce sterilizing immunity will likely not be
possible without a fundamental breakthrough [1,2].
Directed molecular evolution is an effective approach for the
improvement of protein function, ranging from enzyme activities
[44–46] to receptor-ligand interactions [47–49]. Directed molec-
ular evolution includes a process to create large libraries of genes
expressing diverse protein sequences, which are not typically found
in nature, and a means to evaluate the novel proteins for the
desired functional property. Many methods are available to create
sequence diversity and one of the most powerful is in vitro DNA
recombination of naturally occurring homologous genes [44],
which can produce libraries of chimeric protein-coding genes of
high functional quality [50]. The homologous recombination
method offers the important advantage that the DNA sequences
encoding amino acids beneficial to the desired phenotype can be
combined into a single gene. Furthermore, if incremental
improvements in protein function are identified, then additional
rounds of directed molecular evolution can be used to produce
further enhancements [46,51].
Application of directed molecular evolution has led to the
identification of several chimeric dengue envelope proteins that
are each capable of inducing neutralizing antibodies against all
four dengue serotypes [52]. Dupuy et al showed that the
application of directed molecular evolution can improve the
immunogenicity and protective efficacy of the Venezuelan equine
encephalitis virus envelope proteins [53]. Here we report the first
successful use of this technology to improve the neutralization
responses given by HIV-1 Env immunogens. Since evaluation of
immunogenicity requires testing in animals and eventually in
humans, the practical application of directed molecular evolution
to HIV-1 vaccine improvement faces formidable obstacles. In the
present study, we have addressed a number of these issues,
developed an in vitro screening process to down-select candidates
for immunization, implemented high-throughput in vivo screening,
and identified an immunogen capable of inducing a more potent
and broader neutralizing response in rabbits.
Results
Selection and characterization of parental gp120
sequences
The parental gene sequences selected for in vitro homologous
DNA recombination should be similar enough to ensure extensive
recombination while introducing adequate sequence diversity. We
chose 10 env genes from subtype B HIV-1 (Table S1). Pairwise
comparisons of the encoded gp120 amino acid sequences show
similarities between 68 to 96%, which is typical of the diversity
found within a subtype (Figure 1a). The nucleic acid sequences are
80–98% identical (Figure 1a), indicating that there are many
regions where crossovers can occur during in vitro DNA
recombination.
We transfected plasmids expressing each of the ten parental
gp120 genes into CHO-K1 cells and analyzed the resulting
secreted proteins on dot-blots for their ability to bind an anti-His-
tag mAb, a polyclonal serum against gp120, and the human anti-
gp120 mAbs 2G12, b3, b6, and b12. The 2G12 and b12 mAbs
can neutralize many strains of HIV-1 and are therefore considered
broadly neutralizing. The b3 and b6 mAbs compete with b12 for
the CD4 binding site (CD4BS) on gp120 but do not neutralize
typical viral isolates.
Figure 1b shows that all of the parents except 92HT593 and
92US712 produced gp120 proteins that were readily detected with
the polyclonal antiserum, the anti-His-tag mAb, and at least one of
the four human mAbs. The 92HT593 and 92US712 gp120 coding
sequences were found to have internal stop codons, probably
introduced during PCR amplification steps. The expression levels
of the remaining eight parental gp120 proteins were similar as
judged by the anti-His-tag signals and their reactivity to 2G12
(Figure 1b). The differences in binding of the polyclonal anti-Env
serum are likely due to the sequence differences of up to 32%
among these gp120 proteins. The reactivities with the three anti-
CD4BS mAbs (b3, b6 and b12) appeared to segregate into two
groups, i.e., either equally strong (JRCSF, 93US073, 92HT594,
92HT599, 92US657) or equally weak (92HT596, 92US727, 89.6)
(Figure 1b).
Directed molecular evolution of gp120 identifies
antigenic diversity
We used in vitro DNA recombination of parental env genes to
create libraries of chimeric coding sequences expressing gp120
variants. The four human anti-gp120 mAbs were used to
systematically screen the variants for different antigenic pheno-
types. We categorized the binding activities of individual gp120
variants with particular attention to variants that bind the
neutralizing mAbs but not the non-neutralizing mAbs. We
hypothesized that such variants would be superior immunogens
with respect to their ability to induce neutralizing antibodies upon
immunization in animals. The parental gp120 proteins do not
exhibit this specific antigenic phenotype.
Two libraries, L4-A and L4-B, were constructed for this work
using in vitro DNA recombination as illustrated schematically in
Figure 1c. Library L4-A includes all ten parental genes to
maximize sequence diversity, whereas L4-B omits the 92HT593
and 92US712 gp120 to avoid the internal stop codons. In a first
tier of screening, plasmid DNAs from 1000 L4-A clones and 2520
L4-B clones were individually transfected into CHO-K1 cells and
the secreted proteins were initially evaluated for binding to b12
and a pool of b3 and b6 on dot blots. A combined total of 249
plasmids produced variants with positive binding to either reagent
and were re-transfected into CHO-K1 cells for a second tier of
screening to quantify binding to all four mAbs. Figure 1d shows a
representative set of dot-blot images for eighty variants from the
second tier of screening.
After assessing the reactivity with these mAbs, a total of 207
clones from both libraries were categorized into 6 different
antigenic phenotypes (A through F) based on the binding ratios of
b12/b6 and b12/b3, as shown in detail in Table 1. The mAb-
binding characteristics of two representative variants from each
category are shown in Figure 1e. Variants in categories A, B, C
and F demonstrated novel patterns of binding to the three anti-
CD4BS mAbs that differ from those of the parental gp120
proteins, whose binding patterns fall into categories D and E
(Figure 1e).
Novel antigenic and genetic characteristics of gp120
variants
The conditions of the high-throughput dot-blot screening
method were chosen to allow for reproducible quantitative
estimates of mAb binding with a single dilution of the supernatants
from transfected cells. To verify that the novel antigenic properties
held true over a broad range of concentrations using the same dot-
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binding from category A (ST-080, ST-140 and ST-194; see
Figure 2a), and performed transient transfections in triplicate using
the corresponding plasmids. An 8-point serial dilution of each
supernatant was prepared and four replicate blots were made and
reacted with b3, b6, and b12. The results confirmed that all three
gp120 variants bound b12 as strongly as did JRCSF gp120 but had
different b6 binding characteristics, consistent with the screening
results obtained using a single dilution (compare Figure 2a and b).
Binding to b3 was undetectable for all three variant proteins,
representing a greater than 128-fold reduction in the b3-binding
activity relative to that given by JRCSF gp120.
Since the dot-blot assay involves immobilization of antigen to a
solid-phase nitrocellulose matrix, we also investigated whether the
Figure 1. In vitro DNA recombination is used to generate gp120 variants with novel antigenic profiles. (a) Similarities of parental gp120
sequences. The percent identity for nucleotide sequence comparison is in yellow and that for amino acid comparison in blue. (b) Characterization of
the parental gp120 proteins. Supernatants obtained from CHO-K1 cells transfected with the indicated parental gp120 were immobilized on dot-blot
membranes and analyzed by a mouse polyclonal antiserum (Poly Ab), an anti-His-tag mAb (a-H6), and human anti-gp120 mAbs, 2G12, b12, b6 and
b3. (c) Schematic illustration of directed molecular evolution of HIV-1 env genes. (d) Characterization of recombined gp120 variants. Supernatants
from transfection of gp120 variants (columns 1–10) and control plasmids (column 11) as well as eight 1:2 serial dilutions of purified gp120 (column
12) were immobilized on four replicate dot blots and analyzed for reactivity to 2G12, b3, b6 and b12. (e) Antigenic profiles of two representative
gp120 variants from each of six antigenic categories identified (see Table 1). Binding intensities were quantified from dot blots and normalized
against the internal JRCSF control.
doi:10.1371/journal.pone.0020927.g001
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confirmed by immunoprecipitation, which is based on liquid-phase
interactions. Twelve category A variants (Figure 2a) were
radiolabeled and immunoprecipitated by b3, b6, and b12.
Figure 2c shows that all variants bound b12 but not to b3 or b6
inthisassay,consistentwiththescreeningresultsshowninFigure2a.
To study the basis for the altered antigenicity, we chose two
category A gp120 variants, ST-080 and ST-140, and analyzed the
kinetics of interaction with mAbs b6 and b12 using surface
plasmon resonance. As shown in Figure 2d and Table S2, the wild-
type JRCSF gp120 protein binds to b12 with an affinity typical of
antigen-antibody interactions (Ka<10
7); however, b6 binding
affinity is much stronger than that of b12. Compared to JRCSF,
the ST-080 and ST-140 gp120 proteins showed 3.4-fold and 2.1-
fold higher affinity for b12, respectively, due largely to a decreased
off-rate (kd). In contrast, the b6 affinity for both variants was
significantly reduced relative to that of JRCSF or completely
abolished, representing a .10,000-fold change. These results
confirm that the two closely related CD4BS mAb-binding
activities can be segregated by use of directed molecular evolution.
To investigate the genetic relatedness of variants that exhibit
similar antigenic profiles, we analyzed the chimerism (Figure 3a) of
the amino acid sequences of the 12 category A variants studied
above. We identified the parental sequences contained in the
chimeras and found that each variant had a unique recombination
pattern with multiple crossover events (Figure 3a). Phylogenetic
analysis further showed that all 12 gp120 variants were distributed
relatively evenly throughout the sequence space formed by the 10
wild-type parents without any apparent clustering around
individual parents (Figure 3b).
Neutralization responses induced by gp120 variants
Multiple gp120 proteins from each of the antigenic categories
were chosen for immunogenicity studies. The identification of
gp120 variants that preferentially bind the broadly neutralizing
mAb b12 relative to b3 and b6 allowed us to evaluate the
hypothesis that such proteins, which clearly expose the conserved
CD4BS epitope, are superior in their ability to induce neutralizing
antibodies compared to variants that also bind the non-
neutralizing mAbs.
We selected 98 gp120 variants for immunization of rabbits
along with five parental gp120 immunogens (JRCSF, 92HT594,
92US657, 93US073, and 89.6). About three-quarters of the 98
variants came from categories A, B and C: they bind the
neutralizing mAbs 2G12 and b12 and have novel antigenic
profiles compared to parental gp120 proteins. The remaining
variants were chosen from categories D, E and F (Table 1). For in
vivo screening, each gp120-expressing plasmid DNA was injected
three times with electroporation into two rabbits at four-week
intervals. Four weeks after the third DNA injection, each rabbit
received an injection of JRCSF gp120 protein in the expectation
that this would boost any cross-reactive antibodies. The sera
obtained from each rabbit two weeks after the protein boost (Day
98) were screened for their ability to neutralize the SF162
pseudovirus. At a dilution of 1:7.5, ,53% of the variant Env
sequences induced antibodies with .50% neutralization
(Figure 3c), suggesting that the recombined variants largely
retained the immunologically relevant structure of gp120.
There appears to be a weak correlation between antigenic
p h e n o t y p ea n dt h en e u t r a l i z a t i o no fS F 1 6 2( F i g u r e3 c ;T a b l e1 ) .
The percentages of clones that induced .50% neutralization of
SF162 were 52%, 46%, 45%, 80%, 75%, and 38% for categories A–
F, respectively. Variants from categories D and E (parental antigenic
profiles) showed higher positive rates than those from categories A, B,
C,andF(novelantigenicprofiles),suggestingthatevolvingawayfrom
the parental antigenic phenotypes can influence immunogenicity.
Sera that were positive against SF162 (Figure 3c) were further
evaluated using a panel of 9 HIV-1 subtype B pseudoviruses with a
wide spectrum of sensitivity to neutralization. Among the five
parents tested, JRCSF gp120 consistently outperformed other
parents (data not shown). Five gp120 variants (ST-008, ST-051,
ST-148, ST-161 and ST-188) had at least one serum that
performed better than both sera induced by JRCSF gp120 judging
by their cumulative percentage of neutralization against all 9
viruses (Figure 3d). Of these five variants, ST-161 and ST-188 are
category A variants, ST-008 is category B, ST-148 is category C,
and ST-051 is category D (compare Figure 3e to category
definitions in Figure 1e and Table 1). Although these five gp120
variants showed different patterns of binding to the non-
neutralizing mAbs b3 and b6, they all bound strongly to the
neutralizing mAbs 2G12 and b12 (Figure 3e). The five variants
were not related in any obvious way as judged by their chimeric
pattern and showed no similarity in their phylogenetic relation-
ships (Figure 3a,b, filled blue circles). These results show that
directed molecular evolution can give rise to multiple distinct
variants with improved immunogenicity (i.e., increased neutrali-
zation potency) compared to the wild-type parental proteins.
Table 1. Antigenic categories of recombined subtype B gp120 variants.
Category Relative mAb binding* Binding Ratios Representative Phenotype** No. of Variants***
2G12 b12 b6 b3 b12/b6 b12/b3 2G12 b12 b6 b3 Total In vivo SF162
A Var Pos Var Var .2.5 .2.5 +++ +++ 2233 33 17
B Var Pos Var Var ,2.5 .2.5 +++ +++ +++ 2 28 28 13
C Var Pos Var Var Either=1.5–2.5 +++ +++ + + 11 11 5
D Var Pos Pos Pos 0.7–1.5 0.7–1.5 +++ +++ +++ +++ 45 10 8
E Var Neg Neg Neg n/a n/a +++ 22 2 35 8 6
F Var Var Either Pos ,0.7 or n/a +++ 2 +++ +++ 55 8 3
Total 207 98 52
*The cutoff for positive binding is .10% of WT signal; Pos, positive; Neg, negative; Var, varied from negative to positive.
**+++ is $100% reactivity relative to that of WT JRCSF; n/a: not applicable.
***The column labeled ‘‘In vivo’’ indicates the number of variants from each category selected for rabbit immunization. The column labeled ‘‘SF162’’ indicates the
number of variants that induced sera with positive neutralization against SF162 (defined as .50% neutralization at a serum dilution of 1:7.5).
doi:10.1371/journal.pone.0020927.t001
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The ST-008 gp120 induced somewhat stronger neutralization
activity than the other variants tested. We therefore compared the
immunogenicity of the ST-008 and JRCSF gp120 proteins in an
experiment using 8 rabbits for each construct. The amino acid
sequences of these two proteins are aligned in Figure S1. As
before, three electroporation-mediated DNA injections plus one
JRCSF protein boost were used. Sera were collected two weeks
following the third DNA injection (Day 70) and two weeks after
the protein boost (Day 98). All 32 sera were tested for
Figure 2. Confirmation of novel antigenicity. (a) Antigenic profiles of 12 category A gp120 variants. Data were acquired as in Figure 1e. (b)
Characterization of category A gp120 with dot blots. Eight 1:2 serial dilutions of supernatants from triplicate transfection of each indicated gp120
construct were blotted and reacted with b3, b6, b12, and 2G12. Mean and standard deviation of binding intensities at each dilution point are shown.
(c) Characterization of category A gp120 by immunoprecipitation. Indicated gp120 variants were transiently expressed, metabolically labeled,
immunoprecipitated by a mouse polyclonal antiserum (Poly Ab), b12, b6, and b3, and separated on SDS-PAGE. Radiograms of the gels are shown. (d)
Characterization of category A gp120 by surface plasmon resonance analysis. b6 and b12 were captured on to a CM5 chip immobilized with anti-
human antibody and interacted with a range of concentrations of purified gp120 as analyte. Shown are the raw sensor data subtracted by the
response of a reference surface for kinetic analysis (Table S2).
doi:10.1371/journal.pone.0020927.g002
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20927Figure 3. Recombined gp120 variants are genetically diverse and can induce strong neutralization responses. For names shown in (a)
and (b), parents in black; category A gp120 variants in red; non-A variants in blue. Five variants shown in (d) and (e) are indicated as filled blue circles
in (a) through (c). (a) Chimerism of recombined gp120 amino acid sequences. Regions in each variant with sequence identical to each parent have
the matching color to the parent: black, sequences identical to more than one parent; red, point mutation; clear, sequences unmatched with any
parent. (b) Phylogenetic analysis of sequences shown in (a). (c) Recombined gp120 induced neutralization response to HIV-1 SF-162. Selected gp120
variants (Table 1) were used to immunize two rabbits per clone. Antibodies were purified from terminal bleeds and tested at a dilution equivalent to
1:7.5 of sera. The result for the better rabbit for each clone is presented. Red and blue bars indicate results by category A and non-A immunogenically
improved gp120 shown in (a) and (b), respectively. (d) Direct molecular evolution improved immunogenicity. Antibodies of the 5 improved variants
prepared in (c) were analyzed against 9 pseudoviruses at a dilution equivalent to 1:22.5 of the sera. The results for rabbits better than both JRCSF-
immunized ones are presented in stack histogram. (e) Antigenic profile of the 5 most immunogenic recombined gp120 variants. Data were acquired
as in Figure 1e.
doi:10.1371/journal.pone.0020927.g003
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subtype B pseudoviruses that represent a wide spectrum of
sensitivity to a broadly neutralizing human plasma [54] (N16) as
well as to the broadly neutralizing human mAb b12 (Table 2).
As shown in Figure 4a (upper panel) and Table 2, the
neutralization activity of the Day 70 sera from JRCSF-immunized
rabbits seemed to track with the neutralization sensitivity of these
pseudoviruses to N16 human plasma, with the exception of the
JRCSF pseudovirus (autologous neutralization). The Day 70 sera
of ST-008-immunized rabbits neutralized all 15 pseudoviruses to
varying degrees but with a pattern of neutralization that was
different from those given by the JRCSF sera and the N16 plasma.
ST-008 was significantly better than JRCSF at inducing
neutralizing antibodies for 9 out of 15 pseudoviruses by 1.5- to
4.1-fold (P,0.05). On two additional pseudoviruses, BaL and
1196, the neutralizing activities induced by ST-008 trended higher
than those of JRCSF by 1.7-fold (P=0.056 and 0.058,
respectively). In no instance was neutralization by JRCSF sera
significantly greater than that given by ST-008 sera. The superior
neutralization activity induced by ST-008 was seen among both
the sensitive and more resistant pseudoviruses. The geometric
mean titer (GMT) of the ST-008 sera compared to that of the
JRCSF sera was 4.1-fold greater for 6535, 3.2-fold greater for
JRCSF, and 3.3-fold greater for 93BR020; these three viruses are
moderately resistant to neutralization (Table 2).
After the protein boost (Day 98 sera), the differences in
neutralization activity induced by ST-008 and JRCSF were less
striking (Figure 4a, lower panel). The Day 98 sera of ST-008-
immunized rabbits still demonstrated significantly improved
neutralization potency on two relatively resistant viruses, 6535
and 93BR020 (P=0.004 and 0.003, respectively). Although not
statistically significant, GMT values for ST-008 sera were also 3.4-
fold higher against JRCSF and 1.3- to 1.6-fold higher against
SF162, NL-43, QZ4587 and 93TH305. These results confirm the
immunogenic phenotype of ST-008 observed during in vivo
screening.
To map the regions responsible for the improved immunoge-
nicity of ST-008, we constructed four pairs of deletion constructs
using either JRCSF or ST-008 sequences as a backbone:
gp120DV3, gp120DV1V2V3, gp120 Core, and gp120 Cor-
e+V1V2 (Figure 4b). Each of these eight plasmids was used to
immunize 8 rabbits with three DNA injections with electropora-
tion followed by one protein boost, this time using the homologous
Env glycoprotein. The Day 98 sera obtained two weeks after the
protein boost were tested against four pseudoviruses: 6353, BaL,
NL4-3, and SF162. The responses induced by the ST-008
gp120DV3 were reduced by 2.8- to 17.8-fold compared to the
corresponding gp120 sequence (Tables S3 and S4; also compare
Figure 4c to a), suggesting that the V3 region is important for
eliciting the neutralization activity seen in the previous experi-
ment. Nonetheless, the neutralization activity induced by the
modified ST-008 variants was still significantly greater than that
induced by the modified JRCSF immunogens.
The results further showed that all four deletion constructs
derived from ST-008 induced statistically stronger neutralization
responses, when detectable, than did the four JRCSF counterparts
(Figure 4c; Table S3). The neutralization activities elicited by all
deletion constructs were reduced in this homologous prime-boost
immunization experiment compared to that observed with the full-
length ST-008 in the heterologous prime-boost experiment.
However, the degree of reduction for the ST-008-based deletion
constructs was smaller than for the JRCSF counterparts (Table
S4). These results suggest that ST-008 has a backbone of
conserved sequences that is generally more potent at inducing
neutralizing activity compared to JRCSF.
Table 2. Neutralization of pseudoviruses by human plasma, b12 and D70 sera shown in Fig. 4A.
Peudo viruses Subtype Controls Comparison of Day 70 sera
Human plasma N16
(GMT**)
b12
(mg/ml)
JRCSF*
(GMT**)
ST-008*
(GMT**)
Fold
Increase* P value***
SF162 B 12012 0.01 1314 4211 3.2 0.010
NL4-3 B 2128 0.01 89 198 2.2 0.041
BaL B 1176 0.01 99 172 1.7 0.056
VLGCG4 G 576 0.04 31 50 1.6 0.032
1196 B 411 0.48 41 69 1.7 0.058
QZ4589 B 365 0.03 37 64 1.7 0.028
JRCSF B 351 0.06 32 101 3.2 0.038
93BR020 F 298 2.08 14 47 3.4 0.005
93MW960 C 261 0.06 14 12 0.9 .0.100
93BR029 F 242 1.67 17 27 1.6 0.039
6535 B 226 0.64 10 41 4.1 0.001
92HT594 B 147 0.02 15 19 1.3 .0.100
QH0692 B 105 0.10 13 20 1.5 0.009
93TH305 E 87 0.71 21 25 1.2 .0.100
92RW020 A 56 1.67 16 12 0.8 .0.100
aMLV — ,20 .2.50 10 10 1.0 .0.100
*JRCSF & ST-008, immunogens; fold increase, ST-008/JRCSF.
**GMT, geometric mean of IC50 titers for each immunization group.
***Two-tailed homoscedastic t-test using log10 (IC50); n=8.
doi:10.1371/journal.pone.0020927.t002
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20927Figure 4. Characterization of the neutralizing antibody responses induced by ST-008. For (a) and (c), 8 rabbits were immunized with 3
DNA electroporations followed by one protein boost. Sera were evaluated for neutralizing activities against a panel of HIV-1 pseudoviruses.
Neutralizing titers (IC50) by ST-008 and JRCSF immunogens are indicated by solid red triangles and blue solid circles, respectively. The geometric
mean titer for each group is shown as black horizontal bar. The viruses are presented from left to right in increasing resistance to neutralization to
N16 (see Table 2). *** P,0.001; ** P,0.01; * P,0.05; q P,0.10 (see P values in Table 2 and Table S3). (a) Comparison between ST-008 and JRCSF
gp120. Rabbits were boosted with JRCSF gp120. Day 70, after 3 DNA injections; Day 98, after protein boost. The subtype of each non-B virus is
indicated in parentheses. (b) Schematic representation gp120 deletion constructs used in (c). (c) Comparison of 4 pairs of gp120 deletion constructs
made from ST-008 and JRCSF. Rabbits were boosted with homologous proteins. Results of Day 98 sera are shown.
doi:10.1371/journal.pone.0020927.g004
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A high rate of mutation allows HIV-1 to escape from typical
type-specific antibody responses [55–58]. Although several
broadly neutralizing mAbs against the Env have been isolated
from infected individuals [59–65], the conserved epitopes defined
by these mAbs are not adequately immunogenic in the viruses that
circulate in infected individuals or in current forms of Env-based
vaccine candidates [2,3]. Since the wild-type Env glycoproteins
appear incapable of inducing broadly neutralizing antibodies,
novel strategies to modify Env must be pursued. One approach for
discovery of Env-based vaccine candidates is to use directed
molecular evolution to identify proteins that induce broadly
neutralizing antibodies. We characterized hundreds of functional
gp120 sequences with novel genetic and antigenic properties that
are distinct from those of the wild-type Env parents (Figure 1,
Figure 2, Figure 3). Systematic in vivo testing of these variants
identified novel immunogens with clear-cut incremental improve-
ments in neutralization potency (Figure 3, Figure 4).
Although an in vivo screening phase is required for vaccine
discovery, it is important to use relatively simple but high-
throughput in vitro assays to reduce the number of variants selected
for immunization. In the work reported here, we identified gp120
variants that bound the b12 mAb as an indication of the presence
of an intact, broadly conserved neutralizing epitope that overlaps
the functional CD4BS of the Env glycoprotein. We also sought
b12-positive variants that no longer bound the non-neutralizing b3
and b6 mAbs, which also recognize the CD4BS. The b3 and b6
mAbs are representative of the non-neutralizing antibodies to the
CD4BS induced by HIV-1, and we hypothesized that modification
of these epitopes might be beneficial in directing the immune
response to the conserved b12 neutralizing site. We chose rabbits
for in vivo screening because the existing broadly neutralizing
human mAbs often contain heavy-chain CDR3 loops equal to or
longer than 18 amino acids [63,66,67]. Wu et al. [68] have shown
that CDR3 sequences of this length are very rare in mice (0.2%),
but much more frequent in rabbits (8.6%) and humans (15%),
suggesting a potential advantage of using rabbits over mice for
immunization studies.
After in vitro DNA recombination of the parental genes, gp120
protein variants with novel antigenic phenotypes were identified at
high frequency. The phenotypes represented by categories A, B,
C, and F include about 60% of the total variants characterized in
an unbiased screen of two libraries (Table 1; Figure 1). It seemed
likely that the different antigenic categories would be related to the
ability of the gp120 variants to induce neutralizing antibodies in
rabbits. However, the variants appear less likely to generate
positive neutralizing responses to the sensitive SF162 strain of
HIV-1 (Table 1; Figure 3c). Thus, although the ability of a protein
to bind an antibody (antigenicity) does not predict its ability to
induce the corresponding antibody (immunogenicity), the presence
of conserved neutralizing epitopes (defined by binding of 2G12
and b12) in the five improved gp120 immunogens should preserve
the chances that effective neutralizing antibodies can be made to
them (Figure 3d,e). The ST-008 variant, which induced the most
potent neutralizing antibodies, bound b6 and b12 as strongly as
did wild-type JRCSF but exhibited reduced binding to b3. This
might indicate structural changes in the protein that contribute to
its improved neutralization response.
A focus on the lack of binding of non-neutralizing antibodies
like b3 or b6 [59] or on the binding of broadly neutralizing mAbs
such as 2G12, b12, PG9/16, or VRC01 [59,61,65,69] is perhaps
of limited value. The failure to bind a specific antibody such as b6
can result from an inappropriate combination of amino acids that
is not necessarily accompanied by the absence of a functional site
(e.g., the CD4BS). The broadly neutralizing antibodies are the
result of a considerable number of somatic mutation events [69,70]
and optimization of gp120 for strong binding to a specific antibody
will create a protein that binds well to the paratope of the mature
antibody. However, such a protein will not necessarily bind to the
surface-bound germline immunoglobulin of a B cell, binding that
is needed to initiate the humoral immune response [71]. Future
studies will focus on the use of directed molecular evolution to
create immunogens that bind to the germline configuration of
broadly neutralizing antibodies.
Env spikes on the viral surface consist of noncovalently
associated trimers of gp120/gp41 heterodimers [29,72–74].
Several groups have created soluble trimeric (or oligomeric) forms
of Env through various modifications of gp140 [21–25,30,31,39]
and have reported that they induce more potent neutralizing
antibodies than their gp120 counterparts [21,30,31,39]. However,
it is not clear whether these marginal improvements were due to
the oligomerization or simply due to the inclusion of the T-helper
epitopes that are present in the gp41 ectodomain [75,76]. In a
recent study, we found that trimerization per se resulted in no
improvement in immunogenicity for gp140 trimers [28]. The most
potent trimeric gp140 immunogen, gp140-ATC, was no better
than the ST-008 protein when immunization was performed with
the same protocol (data not shown). Beddows et al. [39] studied the
immunogenicity of cleaved and stabilized JRFL gp140 SOS-IP
trimers and evaluated four of the most potent sera using the same
neutralization assay as used here. We therefore compared their
Week 20 and Week 54 data (Table 3 in ref. [39]) with our Week 14
(Day 98) data from the eight rabbits immunized with the ST-008
(Figure 4a). As shown in Table S5, the neutralization activity
obtained on Week 14 in our study was significantly greater than
that obtained on Week 20 in the Beddows et al. study. These results
demonstrate that soluble Env trimer molecules are not necessarily
better immunogens than gp120.
Further work on Env trimers is nonetheless warranted and
Kang et al. [30] have successfully prepared cleaved and stabilized
Env trimers. It is thought that a true mimic of the viral trimeric
complex could induce antibodies to conserved quaternary
structures of the trimer that would be effective in neutralization
of the virus. The PG9/16 and 2909 mAbs bind to a quaternary
structure-specific neutralizing epitope and would appear to fulfill
this requirement [77]. Env trimers in soluble form or presented on
virus-like particles might therefore be able to induce such
neutralizing activities.
Our results show that improved immunogens based on the
HIV-1 gp120 Env glycoprotein can be identified by application of
directed molecular evolution. The more potent neutralizing
responses given by ST-008 compared to JRCSF appear to involve
multiple factors including a superior response when delivered by
DNA vaccination, enhanced V3-based responses, and significantly
improved responses to sequences in the relatively conserved
regions of gp120. It is unclear what antibody specificities are
elicited by ST-008. ST-008 does bind the b6 non-neutralizing
antibody, and it is possible that it induces CD4BS antibodies that
can neutralize b6-sensitive viruses. However, the ST-008 sera do
show neutralization activity against several viruses (92HT594,
92BR020, JRCSF, QH0692, and VLGCG4) that are not sensitive
to b6 [54], and this antibody specificity is therefore unlikely to
account for the improved neutralizing responses of ST-008 shown
in Figure 4a. Deletion of the ST-008 V3 sequences leads to
reduced neutralizing responses. This result suggests ST-008 elicits
V3-targeting antibodies that contribute to its improved immune
response or that loss of V3 in ST-008 alters the conformation of
Directed Molecular Evolution of HIV-1 Envelope
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20927the immunogenic epitope. Deletion of the V3 sequence is not
expected to result in large changes to the remainder of gp120 [78],
but it is possible that conformational changes outside of V3
contribute to this result. A comparison of the heterologous prime-
boost immunization with full-length ST-008 to that of the
homologous prime-boost immunizations with deletion constructs
further suggests that the full-length Env has qualitatively different
immunogenic characteristics than any of the deletion constructs,
or that the heterologous boost explains the qualitatively different
response. We suggest that both of these factors may be involved,
and additional studies will be needed to understand the precise
molecular basis of the improved responses elicited by the ST-008.
These improvements could not have been readily predicted by the
current body of knowledge on Env structure and immunogenicity,
and this consideration highlights the unique advantages of the
directed molecular evolution approach to immunogen discovery
and improvement.
We have focused on gp120 for these initial proof-of-concept
studies. However, the approach used here can be applied to other
Env-based vaccines including those based on soluble trimers,
membrane-bound Env complexes on virus-like particles, or
expression by recombinant viral vectors. Further enhancements
in immunogenicity can potentially be achieved by additional cycles
of the in vitro DNA recombination and in vivo screening processes,
using the improved variants from one round of evolution as the
parents in a subsequent round. This recursive aspect of directed
molecular evolution is analogous to the principles of natural
breeding and classical genetics. The use of directed molecular
evolution thus provides a logical, efficient, and powerful strategy
for the identification of Env variants with improved immunoge-
nicity.
Methods
Cell culture and transient transfection
Chinese Hamster Ovary (CHO)-K1 cells (ATCC No. CRL-61)
were maintained at 37uC in serum-containing medium as previous
described [79]. All transient transfections of CHO-K1 were
performed using LipofectAMINE 2000 (Invitrogen) according to
the manufacturer’s instructions. At 24 hours post-transfection,
cells were washed once, covered with serum-free Opti-MEM I
medium (Invitrogen), and incubated for 3 additional days.
Antibodies, antiserum, and HIV+ human plasma
The human mAbs b3, b6, and b12 recognize discontinuous
epitopes that overlap the functionally conserved CD4BS [59,60].
The 2G12 mAb recognizes a mannose-dependent epitope [61,62]
and was obtained from POLYMUN Scientific, Vienna, Austria. In
this study, the IgG1 form of b12 and the Fab form of b3 and b6
were used in some experiments; in the surface plasmon resonance
analysis and neutralization assays, the IgG1 forms of both b6 and
b12 were used. The HIV
+ human plasma, N16, obtained from
NABI Biopharmaceuticals, exhibited potent and cross-reactive
neutralization as described elsewhere [54]. A mouse polyclonal
antiserum raised against HIV IIIB gp120 was described previously
[28,79]. Mouse anti-His-tag mAb was from GE Healthcare.
Expression vector, genes, and sequence analysis
The mammalian expression vector pMAmp [79] was used to
clone all env genes in this study. Env proteins expressed by pMAmp
contain a human tissue plasminogen activator signal peptide as
well as an N-terminal hexahistidine tag to facilitate quantitation of
expression and protein purification. The wild-type env genes
encoding full-length gp120 were obtained from ten HIV-1 subtype
B strains (Table S1). Selected gp120 genes, including the parental
JRCSF and the recombined variants ST-008, ST-040 and ST-
080, were human-codon optimized and synthesized based on
highly expressed human genes [79,80].
Four gp120 deletion constructs, gp120DV3, gp120DV1V2V3,
gp120 Core, and gp120 Core+V1V2, were created for both
JRCSF and ST-008 from the corresponding humanized genes.
The deletion positions for C1, C5, V1/V2, and V3, as well as the
replacement Gly-Ala-Gly tripeptide in V1/V2 and V3 deletions,
were identical to those of an HXBc2 gp120 Core described
previously [81,82] (see also Figure 4b). Additional gp120 Core
constructs were also generated from their wild-type gp120 genes
and used as DNA transfection controls (see below).
DNA sequencing was performed using ABI BigDye 3.1
chemistry on an ABI 3700 DNA analyzer. Sequence alignment
and similarity for both nucleotide and amino acid sequences were
analyzed in Vector NTI 9.0 (Informax). The chimerism of
recombined gp120 variants was analyzed using proprietary
Maxygen software. Phylogenetic trees were constructed in MEGA
3.0 [83] using the neighbor-joining method and tested by
bootstrap analysis using 1,000 replications.
In vitro DNA recombination and construction of gp120
libraries
In vitro DNA recombination was carried out essentially as
described by Stemmer [84]. The parental env gp120 genes are
amplified by PCR and randomly fragmented to 50 and 200 base
pairs. Various dilutions of the fragments are submitted to a PCR-
like thermal cycling reaction to allow them to reassemble by
successive elongation reactions [84,85]. Once gel analysis indicates
an accumulation of products in the range of the expected size, the
genes are recovered by PCR using two primers that are positioned
inside the original PCR primers that were used to prepare the
fragments. The PCR products of this reaction are then digested,
gel purified, and ligated into the pMAmp vector.
The ligation mixtures were used to transform Escherichia coli
XL10-GoldH ultracompetent cells (Stratagene) and plated onto Q
Trays (Genetix) for an overnight incubation. Individual colonies
were identified and picked with the aid of a Q-Bot robot (Genetix)
and then seeded into the first ten columns of 96-well plates
containing 0.1 ml LB broth with carbenicillin (50 mg/ml).
Columns 11 and 12 of 96-well plates were left empty for controls
to be added in the subsequent screening steps. After overnight
incubation at 37uC, glycerol stocks of the library transformants
were prepared with an aid of a Multimek 96/384-Channel
Automated Pipettor (Beckman Coulter) and stored at 280uC. The
remaining cultures were used to inoculate 96-deep-well blocks
containing 1.2 ml of LB with carbenicillin (50 mg/ml) for plasmid
preparation. After a 20 hour incubation at 37uC, library plasmids
were purified using Qiaprep 96 Turbo Miniprep Kits (Qiagen),
quantitated using 96-well UV plates (Costar) by a SpectraMax 190
microplate spectrophotometer (Molecular Devices), normalized to
100 ng/ml using a Tecan Genesis RSP 100 liquid handling system,
and stored at 220uC until needed for in vitro screening.
High-throughput in vitro screening for antigenicity
CHO-K1 cells were seeded into columns 1 to 11 of 96-well
plates at 40,000 cells/well in 100 ml of serum-containing medium
and incubated at 37uC for 24 hours. Two ml (100 ng) of each clone
from each plate of library plasmids were used to transfect wells in
columns 1 to 10 of a corresponding CHO-K1 plate. The same
amount of 8 plasmid controls, including the pMAmp vector and
the pMAmp constructs expressing JRCSF gp120, 93US073
gp120, 92US727 gp120, 89.6 gp120, JRCSF gp120 Core,
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to transfect wells 1 through 8 in column 11 of each CHO-K1
plate. Twenty-four hours after transfection, the cells were washed
and covered with 200 ml per well of serum-free Opti-MEM I
medium and incubated for 3 days. Once harvested, 40 ml of each
culture supernatant were diluted into 160 ml of PBS in columns 1–
11 of each replicate 96-well plate using the Tecan Genesis RSP
100. To column 12 of each assay plate, 200 ml of 8 1:2 dilutions of
purified JRCSF gp120 protein, starting from 0.5 ng/ml (100 ng
per well), were added as a binding signal control. The entire
contents of each assay plate were applied to an Optitran BA-S83
membrane (0.2 mm; Schleicher & Schuell) held by a 96-well
Minifold I Dot-Blot System (Schleicher & Schuell) with the aid of
the Tecan Genesis RSP 100. The membranes were incubated with
Blocking Buffer (5% non-fat milk, 16PBS, 0.05% Tween) and
probed with human mAbs diluted in the Blocking Buffer, 250 ng/
ml for b3, b6, and b12 and 125 ng/ml for 2G12. The binding
signals were visualized by incubation with a secondary antibody
conjugated with horseradish peroxidase followed by ECL Plus
TM
reagents (GE Healthcare). Each blot was exposed to Kodak XAR
films multiple times to achieve signals within the linear range of
the film for subsequent quantitation using Phoretix Array v2.00
software (Nonlinear Dynamics Ltd). For inter-plate and inter-day
comparison, the signal given by each recombined variant was
normalized to that of the internal JRCSF gp120 transfection
control (column 11, well 2) in the same blot, which was set to
100%. Although 40 ml of culture supernatant were typically used
for dot-blot analysis, a clear differentiation between different
antibody-binding activities was obtained between 2 to 50 mlo f
culture supernatant (see Figure 2b and related discussion in
Results).
Immunoprecipitation
CHO-K1 cells were seeded in 6-well plates at 6610
5 cells per
well in 2 ml of serum-containing medium and grown for 20 hours.
Plasmids expressing gp120 were transfected into each well.
Twenty-four hours after transfection, the cells were washed once
and covered with 3 ml of labeling medium containing 90%
DMEM without Met, 10% dialyzed fetal bovine serum, 1% of
1006 stocks of L-glutamine, sodium pyruvate, and penicillin-
streptomycin, respectively (all from Invitrogen) and incubated for
1 hour. Medium was removed and replaced with 1 ml of labeling
medium+200 mCi
35S-Met/Cys (GE Healthcare). Culture super-
natants were harvested 24 hours later and stored at 220uC. For
each immunoprecipitation reaction, 30 ml of well-suspended
Protein L-agarose (Genomics One International) were washed
with 300 ml of PBS, resuspended into 300 ml of PBS along with
either 4 mg of human mAb or 5 ml of the mouse polyclonal
antiserum, and incubated with slow rotation at 4uC for 1 hour to
allow the formation of an antibody-Protein L-agarose complex.
The complex was washed three times with 300 ml of the serum
medium, resuspended into 300 ml of the same medium, and mixed
with 300 mlo f
35S-label culture supernatant. The reaction was
incubated at 4uC for 2 hours with slow rotation, followed by three
10-minute washes with 500 mM NaCl, 0.02% sodium azide, 0.1%
Triton 6100 in PBS, and one final wash with PBS. After the final
spin, the gp120-antibody-Protein L-agarose complex was resus-
pended into 15 mlo f1 6 LDS loading buffer (Invitrogen) and
separated on a 4–12% SDS-PAGE gel (Invitrogen). The gel was
dried and exposed to a low-energy storage phosphor screen (GE
Healthcare) at room temperature overnight. The image was
acquired and quantitated using a Storm PhosphorImager with
ImageQuant System (GE Healthcare).
Stable cell lines and protein purification
Stable CHO cell lines expressing JRCSF gp120, ST-040, ST-
080, and four ST-008 gp120 deletion constructs (Figure 4b) were
generated using a procedure described previously [79]. Both
production and the metal-chelating affinity purification of these
proteins were also previously reported [79]. In the course of
purifying different gp120 proteins, we have observed that one-step
affinity chromatography does not always produce protein of
sufficient purity. In those cases, we developed a cleanup procedure
using a High Q anion exchange column (Bio-Rad) and a
hydroxyapatite CHT II column (Bio-Rad) to remove impurities
[79]. Using a combination of affinity chromatography and cleanup
procedure, we were able to achieve a desirable purity (.95%) for
both kinetic analysis and animal immunization.
Surface plasmon resonance analysis
A CM5 chip (Biacore) was used to immobilized 18,000 response
units (RU) of goat anti-human gamma chain antibody (KPL, Inc.)
for each of the four flow paths by flowing 50 mg/ml of the
antibody in pH 5.0 acetate buffer (Biacore) at a rate of 10 ml per
minute on a Biacore 2000 (GE Healthcare). The human IgG1
mAbs b6 and b12 (100 RU per cycle) were captured on the
surfaces of flow paths 2 and 4 at a flow rate of 10 ml per minute.
Flow paths 1 and 3 remained unbound to serve as a reference
surface. A range of concentrations of purified gp120 (0, 0.78, 1.56,
3.13, 6.25, 12.5, 25, 50, 100 and 200 nM) was injected onto the
antibody surface in random order, with 25 nM repeated in one
additional cycle, at a flow rate of 30 ml per minute for 2 minutes,
followed by a 5 minute dissociation time. After each association
and dissociation cycle, the goat anti-human gamma chain surface
was regenerated by a 1-minute run followed by a 30-second run of
20 mM HCl at a flow rate of 10 ml per minute. Then, 100 RU of
fresh b6 and b12 were recaptured on the surfaces of flow paths 2
and 4, respectively, for the next cycle. Sensor data were prepared
for kinetic analysis by subtracting the binding response collected
from the corresponding goat anti-human gamma chain reference
surface. The association and dissociation data were fitted
simultaneously to a single-site binding with local mass transfer
model by using BIAevaluation software (Biacore).
Rabbit immunizations
Selected plasmid constructs expressing gp120 variants were used
for mg-scale endotoxin-free DNA preparation and subsequent
animal immunization at Aldevron LLC (Fargo, ND) under animal
use protocol 03001-2011-08-2 Rabbit Electroporation approved
by the local Animal Care and Use Committee. Certified parasite-
free female New Zealand White rabbits were obtained at 8 weeks
of age with an average weight of 1.8–2.3 kg. After a one-week
acclimation period, each rabbit was immunized intramuscularly in
the triceps brachii with three injections of DNA on Days 0, 28 and
56. A total 400 mg of DNA per injection (200 mg in each hind
limb) was delivered with electroporation. On Day 84, each rabbit
received an intraperitoneal injection of 100 mg of JRCSF gp120
protein mixed with 20 ml of aluminum hydroxide gel adjuvant
(ALHYDROGEL ‘‘85’’ 2%, Brenntag Biostor) and brought to a
final volume of 1 ml with endotoxin-free PBS (Sigma). Test bleeds
were obtained on Day 0 and 2 weeks after the third DNA injection
on Day 70. Terminal bleeds were collected 2 weeks after protein
boosting on Day 98.
In the study of four gp120 deletion pairs of JRCSF and ST-008
(Figure 4c), each rabbit received an intramuscular injection of
100 mg of homologous protein mixed with AS02A (GlaxoSmith-
Kline Biologicals) on Day 84 as described elsewhere [28].
Although AS02A-formulated protein vaccine candidates has
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challenge model [87], we found that there is no significant
difference between AS02A and aluminum gel when immunizing
rabbits with the 36DNA electroporation plus 16protein boost
protocol (data not shown), except that AS02A is much easier to
handle than Alum.
Neutralization assays
The neutralizing activities of mAbs, purified antibodies, or
rabbit sera were determined using a pseudovirus-based system as
previously described [28,55,57]. In the initial in vivo screening of
library variants in which 2 rabbits per clone were utilized, we
measured the percent neutralization at a single dilution point using
antibodies purified from rabbit sera using Montage Antibody
Purification Kits (Millipore) to minimize any background inter-
ference (Figure 3c,d). In confirmation studies, in which 8 rabbits
were used for each construct, rabbit serum was use to determine
the IC50 neutralization titers (Figure 4a, c).
Statistical analysis
Two-tailed homoscedastic t-tests were performed by using a
log10 transform of the IC50 values to compare sera from the
JRCSF and the ST-008 groups (Figure 4a, c). P values less than
0.05 were considered statistically significant.
Accession codes
DNA sequences encoding gp120 variants are deposited in
GenBank with the following accession codes: ST-003 (HI550410),
ST-008 (HI550369), ST-051 (HI550370), ST-057 (HI550411),
ST-080 (HI550371), ST-128 (HI550412), ST-140 (HI550372),
ST-148 (HI550373), ST-161 (HI550374), ST-168 (HI550413),
ST-173 (HI550414), ST-188 (HI550375), ST-194 (HI550415),
ST-199 (HI550416), and ST-272 (HI550417).
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Figure S1 Amino acid sequences of JRCSF and ST-008 gp120
proteins. Sequence alignment by ClustalW of JRCSF gp120
(GenBank: AAB03749) and ST-008 excluding the tPA leader
sequence and spacer. Identities=439/488 (89%), Positives=457/
488 (93%), Gaps=12/488 (2%).
(TIFF)
Table S1 Subtype B HIV-1 env genes used for in vitro DNA
recombination.
(DOC)
Table S2 Comparison of kinetic constants for the interactions
between mAbs and wild-type and recombined gp120 proteins.
(DOC)
Table S3 Comparison of Day 98 sera induced by gp120 deletion
constructs.
(DOC)
Table S4 Reduction of neutralization potency in Day 98 sera
induced by gp120 deletion constructs.
(DOC)
Table S5 Comparison of potency of two Env immunogens after
protein boost.
(DOC)
Acknowledgments
We dedicate this manuscript to the memory of Dr. John Curd, physician-
scientist and teacher, who advised and encouraged us in this work. We are
grateful to Kalpana Gupta and Alan Schultz at IAVI, and Feng Gao at
Duke University Medical Center, for many helpful discussions, Kristin
Ostrow, Peggy Powers, and Russell Howard at Maxygen for their insightful
comments on this work. Abigail Alcantara, Bing-Yuan Chen, Asri Gaduh,
Aaron Kurtzman, Albert Lai, Indrani Rebbapragada, and Rossana
Trinidad of Maxygen, provided assistance or technical support in various
aspects of the project. We thank the GIA
TM team at Aldevron LLC, as well
as Michelle Berg and Ronald Robson, for assistance in the rabbit
immunization experiments; Pham Phung and Yolanda Lie of Monogram
Biosciences, Inc. for assistance in neutralization assays; Nathalie Mathy
and Gerald Voss of GlaxoSmithKline Biologicals (Rixensart, Belgium) for
supplying AS02A adjuvant; and Hermann Katinger of POLYMUN
Scientific and the Institute of Applied Microbiology, University of
Agricultural Sciences, Vienna, Austria, for providing the 2G12 antibody.
Author Contributions
Conceived and designed the experiments: SXD LX MBZ PWHIP DRB
TW CJP JAB MC RGW. Performed the experiments: SXD LX WZ ST
RIB HC EBM. Analyzed the data: SXD LX RGW. Contributed reagents/
materials/analysis tools: MBZ PWHIP DRB. Wrote the paper: SXD
RGW.
References
1. Stamatatos L, Morris L, Burton DR, Mascola JR (2009) Neutralizing antibodies
generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat
Med 15: 866–870.
2. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320: 760–764.
3. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al.
(2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to
influenza virus. Nat Rev Microbiol 6: 143–155.
4. Haynes BF, Montefiori DC (2006) Aiming to induce broadly reactive
neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev
Vaccines 5: 579–595.
5. Srivastava IK, Ulmer JB, Barnett SW (2005) Role of neutralizing antibodies in
protective immunity against HIV. Hum Vaccin 1: 45–60.
6. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, et al. (2008)
Profiling the specificity of neutralizing antibodies in a large panel of plasmas
from patients chronically infected with human immunodeficiency virus type 1
subtypes B and C. J Virol 82: 11651–11668.
7. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, et al. (2009)
Factors associated with the development of cross-reactive neutralizing antibodies
during human immunodeficiency virus type 1 infection. J Virol 83: 757–769.
8. Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J (1998)
Neutralizing antibodies are positively associated with CD4+ T-cell counts and
T-cell function in long-term AIDS-free infection. Aids 12: 1591–1600.
9. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, et al. (2007) Broad HIV-1
neutralization mediated by CD4-binding site antibodies. Nat Med 13:
1032–1034.
10. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, et al. (1997) Neutralizing
antibody responses to human immunodeficiency virus type 1 in primary infection
and long-term-nonprogressive infection. J Infect Dis 176: 924–932.
11. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. (2009)
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV
challenge in macaques. Nat Med 15: 951–954.
12. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, et al. (2002)
Determination of a statistically valid neutralization titer in plasma that confers
protection against simian-human immunodeficiency virus challenge following
passive transfer of high-titered neutralizing antibodies. J Virol 76: 2123–2130.
13. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, et al. (1999)
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can
completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
Nat Med 5: 204–210.
14. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al. (2000)
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against
mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200–206.
15. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, et al.
(2001) Postnatal passive immunization of neonatal macaques with a triple
combination of human monoclonal antibodies against oral simian-human
immunodeficiency virus challenge. J Virol 75: 7470–7480.
16. Mascola JR (2003) Defining the protective antibody response for HIV-1. Curr
Mol Med 3: 209–216.
17. (2003) AIDSVAX fails to prove efficacious in large-scale trial. Expert Rev Anti
Infect Ther 1: 527.
Directed Molecular Evolution of HIV-1 Envelope
PLoS ONE | www.plosone.org 12 June 2011 | Volume 6 | Issue 6 | e2092718. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al.
(2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in
Thailand. N Engl J Med 361: 2209–2220.
19. Kwong PD, Wilson IA (2009) HIV-1 and influenza antibodies: seeing antigens in
new ways. Nat Immunol 10: 573–578.
20. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, et al. (2008) Removal of a
single N-linked glycan in human immunodeficiency virus type 1 gp120 results in
an enhanced ability to induce neutralizing antibody responses. J Virol 82:
638–651.
21. Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, et al. (2007) Extensively
cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immuniza-
tion. Proc Natl Acad Sci U S A 104: 10193–10198.
22. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. (2000) A
recombinant human immunodeficiency virus type 1 envelope glycoprotein
complex stabilized by an intermolecular disulfide bond between the gp120 and
gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
J Virol 74: 627–643.
23. Selvarajah S, Puffer BA, Lee FH, Zhu P, Li Y, et al. (2008) Focused dampening
of antibody response to the immunodominant variable loops by engineered
soluble gp140. AIDS Res Hum Retroviruses 24: 301–314.
24. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, et al. (2002) Highly stable
trimers formed by human immunodeficiency virus type 1 envelope glycoproteins
fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76: 4634–4642.
25. Yang X, Farzan M, Wyatt R, Sodroski J (2000) Characterization of stable,
soluble trimers containing complete ectodomains of human immunodeficiency
virus type 1 envelope glycoproteins. J Virol 74: 5716–5725.
26. Morner A, Douagi I, Forsell MN, Sundling C, Dosenovic P, et al. (2009) Human
immunodeficiency virus type 1 env trimer immunization of macaques and
impact of priming with viral vector or stabilized core protein. J Virol 83:
540–551.
27. Hammonds J, Chen X, Fouts T, DeVico A, Montefiori D, et al. (2005) Induction
of neutralizing antibodies against human immunodeficiency virus type 1 primary
isolates by Gag-Env pseudovirion immunization. J Virol 79: 14804–14814.
28. Du SX, Idiart RJ, Mariano EB, Chen H, Jiang P, et al. (2009) Effect of
trimerization motifs on quaternary structure, antigenicity, and immunogenicity
of a noncleavable HIV-1 gp140 envelope glycoprotein. Virology 395: 33–44.
29. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, et al. (2007) A
comparative immunogenicity study of HIV-1 virus-like particles bearing various
forms of envelope proteins, particles bearing no envelope and soluble
monomeric gp120. Virology 366: 245–262.
30. Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, et al. (2009) Structural
and immunogenicity studies of a cleaved, stabilized envelope trimer derived
from subtype A HIV-1. Vaccine 27: 5120–5132.
31. Yang X, Wyatt R, Sodroski J (2001) Improved elicitation of neutralizing
antibodies against primary human immunodeficiency viruses by soluble
stabilized envelope glycoprotein trimers. J Virol 75: 1165–1171.
32. Dey B, Svehla K, Xu L, Wycuff D, Zhou T, et al. (2009) Structure-based
stabilization of HIV-1 gp120 enhances humoral immune responses to the
induced co-receptor binding site. PLoS Pathog 5: e1000445.
33. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, et al. (2008) Cross-
subtype antibody and cellular immune responses induced by a polyvalent DNA
prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26:
1098–1110.
34. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, et al. (2006) Polyvalent
HIV-1 Env vaccine formulations delivered by the DNA priming plus protein
boosting approach are effective in generating neutralizing antibodies against
primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D
and E. Virology 350: 34–47.
35. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, et al. (2006) Antibody
responses elicited in macaques immunized with human immunodeficiency virus
type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with
those elicited during homologous simian/human immunodeficiency virus
SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80: 8745–8762.
36. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, et al. (2001) The ability of
an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen
to elicit neutralizing antibodies against primary HIV-1 isolates is improved
following partial deletion of the second hypervariable region. J Virol 75:
5526–5540.
37. Pantophlet R, Wilson IA, Burton DR (2004) Improved design of an antigen with
enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Eng
Des Sel 17: 749–758.
38. Pantophlet R, Wilson IA, Burton DR (2003) Hyperglycosylated mutants of
human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel
antigens for HIV vaccine design. J Virol 77: 5889–5901.
39. Beddows S, Schulke N, Kirschner M, Barnes K, Franti M, et al. (2005)
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of
the envelope glycoprotein complex of human immunodeficiency virus type 1.
J Virol 79: 8812–8827.
40. Doria-Rose NA, Learn GH, Rodrigo AG, Nickle DC, Li F, et al. (2005) Human
immunodeficiency virus type 1 subtype B ancestral envelope protein is functional
and elicits neutralizing antibodies in rabbits similar to those elicited by a
circulating subtype B envelope. J Virol 79: 11214–11224.
41. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, et al. (2007)
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope
glycoproteins. Virology 360: 218–234.
42. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, et al. (2006)
Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology
352: 438–449.
43. Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, et al. (2006) A
group M consensus envelope glycoprotein induces antibodies that neutralize
subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268–282.
44. Crameri A, Raillard SA, Bermudez E, Stemmer WP (1998) DNA shuffling of a
family of genes from diverse species accelerates directed evolution. Nature 391:
288–291.
45. Ness JE, Kim S, Gottman A, Pak R, Krebber A, et al. (2002) Synthetic shuffling
expands functional protein diversity by allowing amino acids to recombine
independently. Nat Biotechnol 20: 1251–1255.
46. Castle LA, Siehl DL, Gorton R, Patten PA, Chen YH, et al. (2004) Discovery
and directed evolution of a glyphosate tolerance gene. Science 304: 1151–1154.
47. Lazetic S, Leong SR, Chang JC, Ong R, Dawes G, et al. (2002) Chimeric
costimulatory molecules that selectively act through CD28 or CTLA-4 on
human T cells. J Biol Chem 277: 38660–38668.
48. Leong SR, Chang JC, Ong R, Dawes G, Stemmer WP, et al. (2003) Optimized
expression and specific activity of IL-12 by directed molecular evolution. Proc
Natl Acad Sci U S A 100: 1163–1168.
49. Brideau-Andersen AD, Huang X, Sun SC, Chen TT, Stark D, et al. (2007)
Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles
tailored for treatment of chronic viral diseases. Proc Natl Acad Sci U S A 104:
8269–8274.
50. Bacher JM, Reiss BD, Ellington AD (2002) Anticipatory evolution and DNA
shuffling. Genome Biol 3: 1021–1024.
51. Kurtzman AL, Govindarajan S, Vahle K, Jones JT, Heinrichs V, et al. (2001)
Advances in directed protein evolution by recursive genetic recombination:
applications to therapeutic proteins. Curr Opin Biotechnol 12: 361–370.
52. Apt D, Raviprakash K, Brinkman A, Semyonov A, Yang S, et al. (2006)
Tetravalent neutralizing antibody response against four dengue serotypes by a
single chimeric dengue envelope antigen. Vaccine 24: 335–344.
53. Dupuy LC, Locher CP, Paidhungat M, Richards MJ, Lind CM, et al. (2009)
Directed molecular evolution improves the immunogenicity and protective
efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine 27:
4152–4160.
54. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004)
Comprehensive cross-clade neutralization analysis of a panel of anti-human
immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232–13252.
55. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the
neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A
100: 4144–4149.
56. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005)
Neutralizing antibody responses drive the evolution of human immunodeficiency
virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A
102: 18514–18519.
57. Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, et al. (2005) Characterization of
human immunodeficiency virus type 1 (HIV-1) envelope variation and
neutralizing antibody responses during transmission of HIV-1 subtype B.
J Virol 79: 6523–6527.
58. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody
neutralization and escape by HIV-1. Nature 422: 307–312.
59. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, 3rd, et al. (1994)
Recognition properties of a panel of human recombinant Fab fragments to the
CD4 binding site of gp120 that show differing abilities to neutralize human
immunodeficiency virus type 1. J Virol 68: 4821–4828.
60. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, et al.
(2003) Fine mapping of the interaction of neutralizing and nonneutralizing
monoclonal antibodies with the CD4 binding site of human immunodeficiency
virus type 1 gp120. J Virol 77: 642–658.
61. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human
monoclonal antibody 2G12 defines a distinctive neutralization epitope on the
gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70:
1100–1108.
62. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R,
et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type
1 antibody 2G12 recognizes a cluster of alpha1R2 mannose residues on the
outer face of gp120. J Virol 76: 7306–7321.
63. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H (2004) Characterization
of molecular features, antigen-binding, and in vitro properties of IgG and IgM
variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS
Res Hum Retroviruses 20: 755–762.
64. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design
of envelope identifies broadly neutralizing human monoclonal antibodies to
HIV-1. Science 329: 856–861.
65. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad
and potent neutralizing antibodies from an African donor reveal a new HIV-1
vaccine target. Science 326: 285–289.
66. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, et al. (2001)
Crystal structure of a neutralizing human IgG against HIV-1: a template for
vaccine design. Science 293: 1155–1159.
Directed Molecular Evolution of HIV-1 Envelope
PLoS ONE | www.plosone.org 13 June 2011 | Volume 6 | Issue 6 | e2092767. Barbas CF, 3rd, Collet TA, Amberg W, Roben P, Binley JM, et al. (1993)
Molecular profile of an antibody response to HIV-1 as probed by combinatorial
libraries. J Mol Biol 230: 812–823.
68. Wu TT, Johnson G, Kabat EA (1993) Length distribution of CDRH3 in
antibodies. Proteins 16: 1–7.
69. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for
broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:
811–817.
70. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal
structure of PG16 and chimeric dissection with somatically related PG9:
Structure-function analysis of two quaternary-specific antibodies that effectively
neutralize HIV-1. J Virol.
71. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, et al. (2009) Germline-like
predecessors of broadly neutralizing antibodies lack measurable binding to HIV-
1 envelope glycoproteins: implications for evasion of immune responses and
design of vaccine immunogens. Biochem Biophys Res Commun 390: 404–409.
72. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S (2008) Molecular
architecture of native HIV-1 gp120 trimers. Nature 455: 109–113.
73. Zhu P, Liu J, Bess J, Jr., Chertova E, Lifson JD, et al. (2006) Distribution and
three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847–852.
74. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD (2006) Cryo-
electron tomographic structure of an immunodeficiency virus envelope complex
in situ. PLoS Pathog 2: e83.
75. Grundner C, Pancera M, Kang JM, Koch M, Sodroski J, et al. (2004) Factors
limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology
330: 233–248.
76. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, et al. (2006) Cross-
subtype T-cell immune responses induced by a human immunodeficiency virus
type 1 group m consensus env immunogen. J Virol 80: 6745–6756.
77. Wu X, Changela A, O’Dell S, Schmidt SD, Pancera M, et al. (2011)
Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their
Recognition by Antibodies. Journal of virology 85: 4578–4585.
78. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005)
Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025–1028.
79. Du SX, Xu L, Viswanathan S, Whalen RG (2008) Inhibition of V3-specific
cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells.
Protein Expr Purif 59: 223–231.
80. Haas J, Park EC, Seed B (1996) Codon usage limitation in the expression of
HIV-1 envelope glycoprotein. Curr Biol 6: 315–324.
81. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure
of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a
neutralizing human antibody. Nature 393: 648–659.
82. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The
antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:
705–711.
83. Kumar S, Tamura K, Nei M (2004) MEGA3: Integrated software for Molecular
Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5:
150–163.
84. Stemmer WP (1994) DNA shuffling by random fragmentation and reassembly:
in vitro recombination for molecular evolution. Proc Natl Acad Sci U S A 91:
10747–10751.
85. Minshull J, Govindarajan S, Cox T, Ness JE, Gustafsson C (2004) Engineered
protein function by selective amino acid diversification. Methods 32: 416–427.
86. Bojang K, Milligan P, Pinder M, Doherty T, Leach A, et al. (2009) Five-year
safety and immunogenicity of GlaxoSmithKline’s candidate malaria vaccine
RTS,S/AS02 following administration to semi-immune adult men living in a
malaria-endemic region of The Gambia. Hum Vaccin 5: 242–247.
87. Mooij P, van der Kolk M, Bogers WM, ten Haaft PJ, Van Der Meide P, et al.
(1998) A clinically relevant HIV-1 subunit vaccine protects rhesus macaques
from in vivo passaged simian-human immunodeficiency virus infection. AIDS
12: F15–22.
Directed Molecular Evolution of HIV-1 Envelope
PLoS ONE | www.plosone.org 14 June 2011 | Volume 6 | Issue 6 | e20927